Biotechnology

X4 Pharmaceuticals

X4 Pharmaceuticals released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 1.765 M (forecast USD 1.902 M), actual EPS USD -0.69 (forecast USD -0.7875)

X4 Pharmaceuticals released FY2025 9 Months earnings on November 5, 2025 (EST), actual revenue USD 32.55 M, actual EPS USD -4.1224

X4 Pharmaceuticals released FY2025 Semi-Annual Earnings on August 8, 2025 (EST), with actual revenue of USD 30.78 M and EPS of USD -3.5899

X4 Pharmaceuticals released FY2025 Q2 earnings on August 8 (EST), actual revenue USD 1.973 M (forecast USD 1.62 M), actual EPS USD -3.4724 (forecast USD -4.338)

X4 Pharmaceuticals Reports Improved Q2 Earnings

X4 Pharmaceuticals' drug mavorixafor receives FDA Fast Track designation

X4 Pharmaceuticals to Present Data on Chronic Neutropenia Clinical Trial

X4 Pharmaceuticals Reports Significantly Improved Quarterly Earnings

HC Wainwright Maintains X4 Pharmaceuticals at Buy with Raised Price Target

X4 Pharmaceuticals released FY2025 Q1 earnings during market hours on May 1 (EST), actual revenue USD 28.81 M (forecast USD 7.031 M), actual EPS USD 0.0399 (forecast USD -4.3)

X4 Pharmaceuticals stock price falls despite beating revenue forecast

X4 Pharmaceuticals Reports Q1 2025 Financials and XOLREMDI Commercial Progress

X4 Pharmaceuticals Experiences Significant Stock Growth and Launches New Clinical Trial

X4 Pharmaceuticals Inc Reports Earnings and Analyst Ratings

X4 Pharmaceuticals to release FY2025 Q1 earnings report on May 1, 2025, during market hours EST, with forecast revenue of USD 7.031 M and EPS of USD -0.1433

Cantor Fitzgerald Reaffirms X4 Pharmaceuticals Buy Rating with Target Price of $3.00

X4 Pharmaceuticals released FY2024 Q4 earnings during market hours on March 25 (EST), with actual revenue of USD 1.434 M (forecast USD 1.065 M) and actual EPS of USD -5.8868 (forecast USD -5)

X4 Pharmaceuticals released FY2024 annual earnings on March 25 During-Market EST, actual revenue USD 2.557 M (forecast USD 2.193 M), actual EPS USD -5.5878 (forecast USD -4.75)

X4 Pharmaceuticals to Release FY2024 Q4 Earnings on March 25 During-Market EST, Forecast Revenue 1.065 M USD, EPS -0.1666 USD

X4 Pharmaceuticals Signs Exclusive Agreement with Taiba Rare to Distribute Xolremdi for WHIM Syndrome

Lavoro

Sky Quarry

Brand Engagement Network

Datavault AI

Netclass Tech

Atlantic

AgEagle Aerial

Polyrizon

Hyperscale Data

TRAILBLAZER MERGER CORP I USD0.0001 CL A (S/R21/04/2028)

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

X4 Pharmaceuticals(XFOR.US)